TherapeuticsMD (NASDAQ:TXMD) Research Coverage Started at StockNews.com

Equities research analysts at StockNews.com initiated coverage on shares of TherapeuticsMD (NASDAQ:TXMD) in a research report issued to clients and investors on Wednesday. The firm set a “hold” rating on the stock.

TherapeuticsMD Trading Down 0.5 %

NASDAQ TXMD opened at $1.88 on Wednesday. TherapeuticsMD has a fifty-two week low of $1.85 and a fifty-two week high of $4.73. The stock has a 50-day simple moving average of $2.21 and a two-hundred day simple moving average of $2.29.

Institutional Inflows and Outflows

A hedge fund recently bought a new stake in TherapeuticsMD stock. ADAR1 Capital Management LLC purchased a new stake in TherapeuticsMD, Inc. (NASDAQ:TXMD) in the 4th quarter, according to the company in its most recent Form 13F filing with the SEC. The firm purchased 272,160 shares of the company’s stock, valued at approximately $612,000. ADAR1 Capital Management LLC owned 2.57% of TherapeuticsMD as of its most recent SEC filing. Institutional investors and hedge funds own 30.74% of the company’s stock.

TherapeuticsMD Company Profile

TherapeuticsMD, Inc operates as a pharmaceutical royalty company in the United States. It has a license agreement with Mayne Pharma to commercialize the IMVEXXY, BIJUVA, and ANNOVERA prescription prenatal vitamin products sold under the BocaGreenMD and vitaMedMD brand names. The company sells its prescription pharmaceutical products and prenatal vitamin products through wholesale distributors and retail pharmacy distributors.